Calcium Channel Blockers in Neurodegeneration

Calcium Channel Blockers in Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Calcium Channel Blockers in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>L-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>L-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Riluzone</td>
<td>VGCC + Na⁺ channel</td>
</tr>
<tr>
<td class="label">Ziconotide</td>
<td>N-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Cilnidipine</td>
<td>L/N-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Channel Type</td>
<td>Location</td>
</tr>
<tr>
<td class="label">L-type (Cav1.2, Cav1.3)</td>
<td>Dendrites, soma</td>
</tr>
<tr>
<td class="label">N-type (Cav2.2)</td>
<td>Presynaptic terminals</td>
</tr>
<tr>
<td class="label">P/Q-type (Cav2.1)</td>
<td>Presynaptic terminals</td>
</tr>
<tr>
<td class="label">R-type (Cav2.3)</td>
<td>Dendrites</td>
</tr>
<tr>
<td class="label">T-type (Cav3.x)</td>
<td>Thalamus, dendrites</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Channel</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Cav1.2</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Cav1.2</td>
</tr>
<tr>
<td class="label">Cilnidipine</td>
<td>N-type</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Typical Dose</td>

Calcium Channel Blockers in Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Calcium Channel Blockers in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>L-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>L-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Riluzone</td>
<td>VGCC + Na⁺ channel</td>
</tr>
<tr>
<td class="label">Ziconotide</td>
<td>N-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Cilnidipine</td>
<td>L/N-type Ca²⁺ channel</td>
</tr>
<tr>
<td class="label">Channel Type</td>
<td>Location</td>
</tr>
<tr>
<td class="label">L-type (Cav1.2, Cav1.3)</td>
<td>Dendrites, soma</td>
</tr>
<tr>
<td class="label">N-type (Cav2.2)</td>
<td>Presynaptic terminals</td>
</tr>
<tr>
<td class="label">P/Q-type (Cav2.1)</td>
<td>Presynaptic terminals</td>
</tr>
<tr>
<td class="label">R-type (Cav2.3)</td>
<td>Dendrites</td>
</tr>
<tr>
<td class="label">T-type (Cav3.x)</td>
<td>Thalamus, dendrites</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Channel</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Cav1.2</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Cav1.2</td>
</tr>
<tr>
<td class="label">Cilnidipine</td>
<td>N-type</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Typical Dose</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>5-10 mg/day</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>60-120 mg q4h</td>
</tr>
<tr>
<td class="label">Nicardipine</td>
<td>20-40 mg/day</td>
</tr>
<tr>
<td class="label">Amlodipine</td>
<td>5-10 mg/day</td>
</tr>
</table>

Calcium Channel Blockers In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Calcium channel blockers (CCBs) are a class of drugs that inhibit calcium ion influx through voltage-gated calcium channels. These agents have shown promise in modulating calcium dysregulation, a central pathological feature in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@isradipine2019]

Mechanism of Action

Calcium dysregulation is a hallmark of neurodegeneration, leading to excitotoxicity, mitochondrial dysfunction, and neuronal death. CCBs work through several mechanisms: [@calcium2021]

• Voltage-gated calcium channel (VGCC) inhibition: Block L-type, N-type, or P/Q-type calcium channels to reduce calcium influx
• Neuroprotection: Prevent calcium-induced mitochondrial permeability transition and [ROS](/entities/reactive-oxygen-species) generation
• Anti-excitotoxic effects: Reduce glutamate-induced calcium overload
• Improved cerebral blood flow: Enhance vascular dynamics in the neurovascular unit

Disease-Specific Applications

Alzheimer's Disease

• L-type calcium channel blockers may protect against [Aβ](/proteins/amyloid-beta)-induced neurotoxicity
• Reduce [tau](/proteins/tau) phosphorylation through calcium/calmodulin-dependent pathways
• Clinical trials with nimodipine, nicardipine showed mixed results

Parkinson's Disease

• Dihydropyridine CCBs (isradipine) protect dopaminergic [neurons](/entities/neurons)
• Reduce calcium dysregulation in substantia nigra pars compacta (SNpc) neurons
• Isradipine Phase II trial for early PD (NINDS study)
• May slow disease progression through neuroprotection

Amyotrophic Lateral Sclerosis

• Riluzole indirectly modulates calcium channels
• N-type and P/Q-type CCBs may protect motor neurons
• reduce glutamate excitotoxicity

Key Drug Candidates

Therapeutic Implications

Calcium channel blockers represent a disease-modifying approach rather than symptomatic treatment. Key considerations:

• Timing: Early intervention may be most effective
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration: Newer dihydropyridines show improved CNS penetration
• Combination therapy: Potential synergistic effects with other neuroprotective agents
• Side effects: Hypotension, peripheral edema, cardiac effects

Research Directions

• Development of neuron-selective CCBs with improved BBB penetration
• Biomarker-driven patient selection
• Combination trials with dopamine agonists or MAO-B inhibitors in PD
• Multi-target approaches addressing calcium homeostasis

See Also

• [Dopaminergic Vulnerability Pathway](/mechanisms/dopaminergic-vulnerability)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [Excitotoxicity in Neurodegeneration](/mechanisms/excitotoxicity)
• [Parkinson's Disease Treatments](/therapeutics/parkinson-disease-treatment)
• [Neuroprotection Strategies](/therapeutics/neuroprotection)

Calcium Dysregulation in Neurodegeneration

The Calcium Hypothesis

Calcium (Ca²⁺) dysregulation is a central mechanism in neurodegeneration:

Calcium Channels in the Brain

Therapeutic Target Rationale

L-Type Channels (Cav1.2, Cav1.3)

• Cav1.3: Regulated by dopamine, implicated in PD
• Neuronal L-type: Ca²⁺ entry triggers pro-survival pathways
• Aging: L-type channels become dysfunctional

N-Type and P/Q-Type

• Presynaptic inhibition: Reduce neurotransmitter release
• Pain pathways: N-type blockers are analgesics
• Synaptic plasticity: P/Q-type regulate release

Disease-Specific Applications

Parkinson's Disease

Alzheimer's Disease

• Calcium homeostasis: Disrupted in AD neurons
• Amyloid interaction: [Aβ](/proteins/amyloid-beta) affects Ca²⁺ channels
• L-type blockers: May protect against Aβ toxicity
• Clinical trials: Ongoing for disease modification

Amyotrophic Lateral SALS

• Motor neuron vulnerability: Ca²⁺ dysregulation
• Excitotoxicity: Key mechanism in ALS
• Ziconotide: N-type blocker (intrathecal)
• Clinical trials: Limited evidence

Huntington's Disease

• Channel dysregulation: Mutant [HTT](/proteins/htt-protein) affects Ca²⁺ signaling
• Mitochondrial function: Ca²⁺ handling impaired
• L-type channels: Therapeutic target
• Preclinical: Positive results in models

Clinical Considerations

Dosing and Administration

Adverse Effects

• Hypotension: Most common, especially with isradipine
• Peripheral edema: Fluid retention
• Reflex tachycardia: Counter-regulatory response
• Cognitive effects: Generally minimal
• Drug interactions: CYP3A4 substrates

Contraindications

• Heart failure: May worsen cardiac function
• Severe aortic stenosis: Fixed outflow obstruction
• Second/third degree AV block: Without pacemaker

External Links

• [PubMed - Calcium Channel Blockers Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=calcium+channel+blockers+neurodegeneration)
• [NIH - Calcium Signaling in AD](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655122/)
• [ScienceDirect - L-type Calcium Blockers](https://www.sciencedirect.com/topics/medicine-and-dentistry/calcium-channel-blockers)
• [Nature - Calcium Dysregulation](https://www.nature.com/articles/nrn1434)

Background

The study of Calcium Channel Blockers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

• [PubMed - Calcium Channel Blockers Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=calcium+channel+blockers+neurodegeneration)
• [NIH - Calcium Signaling in AD](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655122/)
• [ScienceDirect - L-type Calcium Blockers](https://www.sciencedirect.com/topics/medicine-and-dentistry/calcium-channel-blockers)
• [Nature - Calcium Dysregulation](https://www.nature.com/articles/nrn1434)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622) &#x1f504;
• [Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Calcium Channel Blockers in Neurodegeneration discovered through SciDEX knowledge graph analysis: